Auxilium Pharmaceuticals, Inc. (AUXL): Huge Potential For First Line Therapy For Frozen Shoulder

Page 1 of 2

Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL)Editor’s Note: This article has been amended to better describe Auxilium’s drugs and pipeline prospects. Motley Fool apologizes for the inaccuracies.

Xiaflex from Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) is used to treat Dupuytren’s contracture. The drug recently increased its revenue potential after announcing a positive outcome for the treatment of Frozen Shoulder Syndrome (FSS), a related disease that affects one in 20 adults worldwide. If approved, Xiaflex will be the only anti-FSS drug in the market.

The disease

FSS, or Adhesive Capsulitis, is a painful condition of the shoulder. It happens due to thickening of capsular collagen that affects contraction of shoulder joints. Patients are unable to move their shoulders and experience severe pain. It is estimated that nearly 2-5% of the adult population, especially women, develops FSS. Around 10-20% diabetic patients – 36% in case of insulin dependence – have FSS. The disease can last from one to 3.5 years. It is estimated that approximately 300,000 FSS patients are going through treatment every year.

Xiaflex

Xiaflex is already approved by the FDA in the U.S., Europe and Canada to treat adults with Dupuytren’s contracture. It is a disease caused due to thickening and shortening of cords in the hand that lead to bending of one or more fingers toward the palm. This disease has similarities with FSS in the collagen accumulation; one disease is in fact called the other’s cousin. Most people who develop one develop the other disease because of similarities in cellular biochemistry – so it is not surprising that a treatment for one may be used to treat the other.

Performance

During the first quarter of 2013, Xiaflex sales were $20.7 million, up 39% compared to $14.9 million last year. The growth was due to significant rise in international sales compensating decreasing sales in the U.S.

Overall, Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) reported net revenues of $66.2 million, down by 10% compared to $73.6 million in the same period last year. The decline was due to 23% decrease in total sales of Testim, a treatment for males with low to no testosterone developed by Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), and 5% decline in Xiaflex sales in the U.S. The company reported negative earnings due to high operating expenses resulting from SG&A and R&D expenses. Cash, cash equivalents and short term investments as of March 31, 2013 were $467.8 million, compared to $157.4 million as of December 31, 2012. That is a 3-fold increase.

Additional indications

Xiaflex has completed its Phase III trials for the treatment of Peyronie’s disease, for which it showed positive results, and in Phase I for Cellulite. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for the treatment of PD, which the FDA accepted on December 27, 2012. Under the Prescription Drug User Fee Act (PDUFA), the FDA is expected to take action on the application by September 6, 2013.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!